Metformin in non-alcoholic steatohepatitis - PubMed
G Marchesini, M Brizi, G Bianchi, S Tomassetti, M Zoli, N Melchionda
Article ImagesMetformin in non-alcoholic steatohepatitis
G Marchesini et al. Lancet. .
Abstract
There is no established treatment for steatohepatitis in patients who are not alcoholics. This disease is a potentially progressive liver disease associated with hepatic insulin resistance. Only a weight-reducing diet in overweight patients has proved effective. We treated 20 patients who had steatohepatitis but were not alcoholics with metformin (500 mg three times a day for 4 months), an agent that improves hepatic insulin sensitivity. When compared with the six individuals not complying with treatment, long-term metformin significantly reduced mean transaminase concentrations, which returned to normal in 50% of actively-treated patients. Also, insulin sensitivity improved significantly and liver volume decreased by 20%. Similar data have been reported in insulin-resistant ob/ob mice with fatty liver. A randomised-controlled study is needed.
Comment in
-
Metformin in non-alcoholic steatohepatitis.
Urso R, Visco-Comandini U. Urso R, et al. Lancet. 2002 Jan 26;359(9303):355-6. doi: 10.1016/S0140-6736(02)07566-9. Lancet. 2002. PMID: 11830232 No abstract available.
Similar articles
-
Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. Bugianesi E, et al. Am J Gastroenterol. 2005 May;100(5):1082-90. doi: 10.1111/j.1572-0241.2005.41583.x. Am J Gastroenterol. 2005. PMID: 15842582 Clinical Trial.
-
Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
Kadayifci A, Merriman RB. Kadayifci A, et al. Am J Gastroenterol. 2006 Jun;101(6):1396; author reply 1396-7. doi: 10.1111/j.1572-0241.2006.00595_1.x. Am J Gastroenterol. 2006. PMID: 16771968 No abstract available.
-
Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, Coban S, Erden E, Soykan I, Emral R, Uysal AR, Ozden A. Idilman R, et al. Aliment Pharmacol Ther. 2008 Jul;28(2):200-8. doi: 10.1111/j.1365-2036.2008.03723.x. Epub 2008 Apr 25. Aliment Pharmacol Ther. 2008. PMID: 18445142 Clinical Trial.
-
Hookman P, Barkin JS. Hookman P, et al. Am J Gastroenterol. 2003 Sep;98(9):2093-7. doi: 10.1111/j.1572-0241.2003.07670.x. Am J Gastroenterol. 2003. PMID: 14499793 Review.
-
Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Angelico F, et al. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166. doi: 10.1002/14651858.CD005166.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253544 Review.
Cited by
-
Metformin and the Liver: Unlocking the Full Therapeutic Potential.
Perazza F, Leoni L, Colosimo S, Musio A, Bocedi G, D'Avino M, Agnelli G, Nicastri A, Rossetti C, Sacilotto F, Marchesini G, Petroni ML, Ravaioli F. Perazza F, et al. Metabolites. 2024 Mar 25;14(4):186. doi: 10.3390/metabo14040186. Metabolites. 2024. PMID: 38668314 Free PMC article. Review.
-
Hu J, Chen Z, Zhou Y, Li Y, Liu J, Mi Y, Wang L, Jiang F, Li P. Hu J, et al. Immun Inflamm Dis. 2024 Mar;12(3):e1226. doi: 10.1002/iid3.1226. Immun Inflamm Dis. 2024. PMID: 38533910 Free PMC article.
-
Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease.
Lv T, Lou Y, Yan Q, Nie L, Cheng Z, Zhou X. Lv T, et al. Lipids Health Dis. 2024 Feb 17;23(1):50. doi: 10.1186/s12944-024-02037-9. Lipids Health Dis. 2024. PMID: 38368351 Free PMC article.
-
Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing.
Hua Y, Zheng Y, Yao Y, Jia R, Ge S, Zhuang A. Hua Y, et al. J Transl Med. 2023 Jun 21;21(1):403. doi: 10.1186/s12967-023-04263-8. J Transl Med. 2023. PMID: 37344841 Free PMC article. Review.
-
Chiu HY, Tsai SC, Tsai FJ, Lo YH, Cheng CC, Liu TY, Jhan SR, Yang JS, Chiu YJ. Chiu HY, et al. In Vivo. 2023 May-Jun;37(3):1037-1046. doi: 10.21873/invivo.13178. In Vivo. 2023. PMID: 37103096 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous